The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Pembro +/- ipi in metastatic NSCLC: KEYNOTE-598
Pembrolizumab monotherapy has been shown to significantly prolong survival in metastatic non-small cell lung cancer (NSCLC) compared to platinum-doublet chemotherapy. Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the results of the Phase III KEYNOTE-598 trial (NCT03302234) of pembrolizumab alone or combined with ipilimumab in patients with metastatic NSCLC, designed to expand on this finding. 568 patients with a PD-L1 tumor proportion score (TPS) ≥50% were included in the trial and followed-up for a median of 20 months. The results showed that adding ipilimumab caused more adverse events than pembrolizumab-placebo, causing a higher rate of treatment discontinuation. Additionally, no benefit was seen when ipilimumab was added to pembrolizumab. The median overall survival, progression-free survival and duration of response was comparable in the pembrolizumab-ipilimumab arm and the pembrolizumab placebo arm. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
Disclosures
Honoraria: Amgen, AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Mirati, Merck, Novartis, Pfizer, Regeneron, Roche.
